Published in Cancer Weekly, August 1st, 2006
Professor Alan Burnett Chairman of the UK National Cancer Research Institute Hematological Study Group said, "Clofarabine was able to, at least, match the treatment outcome in patients who are fit for intensive chemotherapy and, importantly does not cause alopecia and mucositis, side effects typically seen with intensive treatment."
The clofarabine data was from BIOV-121, Bioenvision's acute...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.